Price
$4.88
Decreased by -5.24%
Dollar volume (20D)
23.20 M
ADR%
6.52
Earnings report date
May 8, 2025
Shares float
146.66 M
Shares short
11.21 M [7.64%]
Shares outstanding
153.94 M
Market cap
792.79 M
Beta
1.21
Price/earnings
N/A
20D range
4.05 6.07
50D range
3.24 6.07
200D range
2.03 6.07

Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois.

The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.

It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism.

The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
Mar 4, 25 -0.03
Increased by +70.00%
-0.02
Decreased by -50.00%
Nov 8, 24 -0.11
Decreased by -22.22%
-0.09
Decreased by -22.22%
Aug 8, 24 -0.10
Increased by +28.57%
-0.11
Increased by +9.09%
May 9, 24 -0.14
Decreased by -16.67%
-0.12
Decreased by -16.67%
Mar 6, 24 -0.10
Increased by 0.00%
-0.10
Nov 9, 23 -0.09
Increased by +43.75%
-0.12
Increased by +25.00%
Aug 8, 23 -0.14
Increased by +26.32%
-0.13
Decreased by -7.69%
May 9, 23 -0.12
Increased by +52.00%
-0.17
Increased by +29.41%
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Dec 31, 24 60.10 M
Increased by +35.39%
-5.11 M
Increased by +61.81%
Decreased by -8.51%
Increased by +71.80%
Sep 30, 24 54.27 M
Increased by +12.31%
-15.74 M
Decreased by -29.12%
Decreased by -29.00%
Decreased by -14.96%
Jun 30, 24 48.06 M
Increased by +26.46%
-15.01 M
Increased by +24.38%
Decreased by -31.22%
Increased by +40.20%
Mar 31, 24 40.64 M
Increased by +22.42%
-18.98 M
Decreased by -12.75%
Decreased by -46.71%
Increased by +7.90%
Dec 31, 23 44.39 M
Increased by +16.79%
-13.39 M
Increased by +32.52%
Decreased by -30.16%
Increased by +42.22%
Sep 30, 23 48.32 M
Increased by +45.56%
-12.19 M
Increased by +54.19%
Decreased by -25.23%
Increased by +68.53%
Jun 30, 23 38.01 M
Increased by +50.19%
-19.84 M
Increased by +24.22%
Decreased by -52.20%
Increased by +49.55%
Mar 31, 23 33.20 M
Increased by +50.39%
-16.83 M
Increased by +50.07%
Decreased by -50.71%
Increased by +66.80%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY